成都普瑞法科技开发有限公司欢迎您!
ISO ISO
CNAS CNAS
高新技术企业 高新技术企业
USP USP
知识产权管理体系认证证书 知识产权管理体系认证证书

文献列表

专业生产定制高含量植提产品和中药成分

您当前的位置:
期刊名:Pharmaceutical Biology
文献编号:
文献地址: https://www.tandfonline.com/doi/full/10.1080/13880209.2020.1855212
发表日期:17 Dec 2020
Abstract

Context

Xiayuxue decoction (XYXD), a traditional Chinese medicine, is used for treating liver disease. However, the potential active constituents and mechanisms are still unclear.

Objective

To explore the main active fraction extracts, active ingredients and possible mechanisms of XYXD for anti-hepatic fibrosis.

Materials and methods

Different fractions including ethyl acetate fraction (EF) were prepared from XYXD. These fractions, especially EF, were used to evaluate cell viability, proliferation, cell cycle, cytotoxicity and activation in hepatic stellate cells (HSCs). Liver fibrosis model was established by CCl4 in C57BL/6 mice, and allocated to CCl4 group, XYXD group and EF group with normal mice as control. Further, mitochondrial apoptosis-related proteins of HSCs, destruction and angiogenesis of liver sinusoidal endothelial cells (LSECs) and active ingredients of EF were evaluated.

Results

The inhibition of proliferation, increase of S or/and G2/M phase population and suppression of α-SMA and COL-1 expression were obeserved in EF treated-JS1 and -LX2. Liver fibrosis-related indicators were improved by EF similar to XYXD in vivo. EF induced the apoptosis of HSCs in CCl4-induced fibrosis, and inhibited the expression of HSCs apoptosis pathway-related proteins (JNK and p38-MAPKs), and LSECs destruction and angiogenesis. Multiple ingredients (emodin, rhein, aloe-emodin, prunasin) in EF have shown inhibited the activation of JS1.

Discussion and Conclusion

EF was the main active fraction extracts of XYXD, and the underlying mechanisms might relate to induction of HSCs apoptosis. Emodin, rhein, aloe-emodin and prunasin were main active ingredients of EF, which provides a potential drug for the treatment of liver fibrosis.


The R. palmatum (batch number: 180223), P. persica Batsch (batch number: 180202), and E. sinensis (batch number: 180116) were purchased from Shanghai Kangqiao Chinese Medicine Tablet Co., Ltd. (Shanghai, China) and authenticated by associate professor Wei Liu, Institute of Liver Diseases, Shanghai University of Traditional Chinese Medicine. Amygdalin (Amy, 1), aloe-emodin (Alo, 9), rhein (Rhe, 10), emodin (Emo, 11), chrysophanol (Chr, 12) and physcion (Phy, 13) were purchased from Dalian Meilun Biotechnology Co., Ltd. (Dalian, China). Aloe-emodin-8-O-β-d-glucopyranoside (A-8-G, 3), rhein-8-O-β-d-glucopyranoside (R-8-G, 4), emodin-1-O-glucoside (E-1-G, 5), emodin-8-glucoside (E-8-G, 6), chrysophanol-8-O-β-d-glucopyranoside (C-8-G, 7) and chrysophanol-1-O-β-d-glucopyranoside (C-1-G, 8) were purchased from Chengdu Biopurify Phytochemicals Ltd. (Chengdu, China). Prunasin (Pru, 2) was obtained from Yuanye Biotech Company (Shanghai, China).